Gastrointestinal toxicity of chemotherapeutic agents.
Chemotherapy-induced toxicities commonly occur in sites within the gastrointestinal (GI) tract and account for dose-limiting effects. These toxicities are major contributing factors to dose reduction, delays, and cessation of cancer treatment. Through intensive therapies including surgery, combination chemotherapy, hormonal therapy, and targeted therapy, an increasing number of patients with cancer are experiencing improved survival and long-term disease-free survival, as well as palliation of disease-related symptoms. Thus, GI toxicities should be predicted and appropriate interventions initiated to prevent them when possible and provide effective supportive measures and comprehensive follow-up care. This review will discuss the etiology, incidence, prevention, and treatment of GI toxicities of cancer chemotherapy.
Mitchell
Edith P
EP
Division of Medical Oncology, Thomas Jefferson University, Philadelphia, PA 19107, USA. Edith.Mitchell@jefferson.edu
D000818:Animals; D000932:Antiemetics / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects*; D005767:Gastrointestinal Diseases / Q000139:chemically induced* / Q000453:epidemiology / Q000517:prevention & control*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy
D000932:Antiemetics; D000970:Antineoplastic Agents